INSMCongressional Stock Trades
Insmed, Inc.
Pharmaceutical Preparations
Congressional stock trades in Insmed, Inc. (INSM) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
7
Politicians Trading
2
Last Traded
Jun 10, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Josh GottheimerD | Jul 7, 2026 | Jun 10, 2026 | Sell | $1,001 - $15,000 | +30.61% |
| Gilbert Ray Cisneros, Jr.D | Nov 18, 2025 | Oct 3, 2025 | Sell | $1,001 - $15,000 | -23.64% |
| Gilbert Ray Cisneros, Jr.D | Oct 10, 2025 | Sep 22, 2025 | Sell | $1,001 - $15,000 | -17.26% |
| Gilbert Ray Cisneros, Jr.D | Sep 12, 2025 | Aug 8, 2025 | Sell | $1,001 - $15,000 | +9.54% |
| Gilbert Ray Cisneros, Jr.D | Aug 14, 2025 | Jul 7, 2025 | Sell | $1,001 - $15,000 | +23.78% |
| Josh GottheimerD | Jul 16, 2025 | Jun 16, 2025 | Buy | $1,001 - $15,000 | +18.12% |
| Josh GottheimerD | May 14, 2025 | Apr 9, 2025 | Sell | $1,001 - $15,000 | +77.65% |
Price History
About Insmed, Inc.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.